BLUE BELL, Pa., Feb. 24, 2011 /PRNewswire/ — Inovio
Pharmaceuticals, Inc. (NYSE Amex:
INO), a leader in the development of therapeutic and preventive
vaccines against cancers and infectious diseases, announced today
that Dr. J. Joseph Kim, President and CEO will present a company
overview at the Cowen & Co. 31st Annual Health Care Conference
being held March 7-9 at the Boston Marriott Copley Place in Boston,
Inovio Presentation: March 9, 2011 at 8:00 am ESThttp://www.cowen.com/UpcomingConferences.html
About Inovio Pharmaceuticals, Inc. Inovio is developing a new
generation of vaccines, called DNA vaccines, to treat and prevent
cancers and infectious diseases. These SynCon™ vaccines are
designed to provide broad cross-strain protection against known as
well as newly emergent strains of pathogens such as influenza.
These vaccines, in combination with Inovio’s proprietary
electroporation delivery devices, have been shown to be safe and
generate significant immune responses. Inovio’s clinical programs
include HPV/cervical dysplasia and cancer (therapeutic), avian flu
(preventive), and HIV vaccines (both preventive and therapeutic).
Inovio is developing universal influenza and other vaccines in
collaboration with scientists from the University of Pennsylvania.
Other partners and collaborators include Merck, National Cancer
Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines
Trial Network, University of Southampton, and PATH Malaria Vaccine
Initiative. More information is available at www.inovio.com.
This press release contains certain forward-looking
statements relating to our business, including our plans to develop
electroporation-based drug and gene delivery technologies and DNA
vaccines and our capital resources. Actual events or r